Year: 2022

  • Prof. Sylviane Muller awarded prestigious Legion d’honneur.’

    ImmuPharma PLC (LSE:IMM; Euronext Growth Brussels: ALIMM),  the specialist drug discovery and development company, is delighted to announce that Prof. Sylviane Muller, inventor of Lupuzor™ and P140 technology and a key collaboration partner, has been awarded the highly prestigious Legion d’honneur Award. The ‘Remise des insignes d’officier de la Légion d’honneur’ was presented to Prof.…

  • Corporate Update

    ImmuPharma PLC (LSE:IMM; Euronext Growth Brussels: ALIMM),  the specialist drug discovery and development company, is pleased to provide an update in respect to a number of corporate and scientific activities within the business over the last period. Introduction Following the major change in our managerial and Board structure over the last couple of months, the…

  • INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2021

    ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2021 (the “Period”). Key Highlights (including post Period review) Financials Financial performance in line with expectations over the Period Cash balance of £4.2m as…

  • Director & PDMR Share Purchases

    ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that each member of the Board of Directors and PDMR, Ewa Flynn (Chief Financial Officer) have on 23 & 24 August 2021 purchased in total 670,000 ordinary shares of 10p in the Company (“Ordinary Shares”). Details of the share purchases…

  • Lanstead Capital TR1

    TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS To download click here

  • FDA approves the Lupzuor™ PK study

    ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, is delighted to announce that the US Food & Drug Administration (“FDA”) has approved the commencement of the pharmacokinetic (“PK”) study, as part of the new optimised international Phase 3 trial of Lupuzor™. The PK study is a Phase I study…

  • BOARD CHANGES

    ImmuPharma PLC (LSE:IMM; Euronext Growth Brussels: ALIMM),  the specialist drug discovery and development company, provides notification of changes to its Board of Directors. Over the last year, ImmuPharma has continued to progress Lupuzor™ toward its international Phase 3 trial in conjunction with its partner, Avion Pharmaceuticals. In addition, the Company has been active in repositioning…

  • BOARD APPOINTMENT

    ImmuPharma PLC (LSE:IMM | Euronext Growth Brussels: ALIMM),  the specialist drug discovery and development company, is delighted to announce the appointment of Dr Tim Franklin, Chief Operating Officer, to the Board of Directors. Tim has worked with ImmuPharma for over three years, initially as a consultant and more recently was appointed as Chief Operating Officer…

  • 2021 RESULT OF ANNUAL GENERAL MEETING – ALL RESOLUTIONS PASSED

    ImmuPharma PLC (LSE:IMM | Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, held its AGM earlier today, in accordance with COVID-19 guidance. The Company is pleased to announce that all resolutions were duly passed. The results of each resolution were as follows:   As at the date of the AGM, the number…

  • FDA to agree on the Lupzuor™ PK study via a written response to “Type

    ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that its US Lupuzor™ partner, Avion Pharmaceuticals (“Avion”) has received a positive response from the US Food & Drug Administration (“FDA”) for a “Type C” meeting. The FDA has advised that they do not require a formal face to face…